C16.1-C16.6, C16.8-C16.9 C16.1 Fundus of stomah C16.2 Body of stomah C16.3 Gastri antrum C16.4 Pylorus C16.5 Lesser urvature of stomah, NOS C16.6 Greater urvature of stomah, NOS C16.8 Overlapping lesion of stomah C16.9, NOS CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval CS Site-Speifi Fator 1 Clinial Assessment of Regional Lymph Nodes CS Site-Speifi Fator 2 Speifi Loation of Tumor CS Site-Speifi Fator 3 CS Site-Speifi Fator 4 CS Site-Speifi Fator 5 CS Site-Speifi Fator 6 CS Site-Speifi Fator 7 CS Site-Speifi Fator 8 CS Site-Speifi Fator 9 CS Site-Speifi Fator 10 CS Site-Speifi Fator 11 CS Site-Speifi Fator 12 CS Site-Speifi Fator 13 Carinoembryoni Antigen (CEA) CS Site-Speifi Fator 14 Carinoembryoni Antigen (CEA) Lab Value CS Site-Speifi Fator 15 CA 19-9 Lab Value CS Site-Speifi Fator 16 CS Site-Speifi Fator 17 CS Site-Speifi Fator 18 CS Site-Speifi Fator 19 CS Site-Speifi Fator 20 CS Site-Speifi Fator 21 CS Site-Speifi Fator 22 CS Site-Speifi Fator 23 CS Site-Speifi Fator 24 CS Site-Speifi Fator 25 Involvement of Cardia and Distane from Esophagogastri Juntion (EGJ) The following tables are available at the ollaborative staging website: Histology Inlusion Table AJCC 7th ed. Histology Exlusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage Lymph Nodes Clinial Evaluation 7th Table Lymph Nodes Pathologi Evaluation 7th Table Also Used When CS Reg Nodes Eval is Not d Lymph Nodes Clinial Evaluation 6th Table Lymph Nodes Pathologi Evaluation 6th Table Also Used When CS Reg Nodes Eval is Not d CS Tumor Size (Revised: 06/30/2008) 000 No mass/tumor found 001-988 001-988 millimeters (ode exat size in millimeters) 989 989 millimeters or larger 990 Mirosopi fous or foi only, no size of fous given 29 April 2010 Part II - Upper GI - 58 Version 02.02.00
991 Desribed as "less than 1 m" 992 Desribed as "less than 2 m," or "greater than 1 m," or "between 1 m and 2 m" 993 Desribed as "less than 3 m," or "greater than 2 m," or "between 2 m and 3 m" 994 Desribed as "less than 4 m," or "greater than 3 m," or "between 3 m and 4 m" 995 Desribed as "less than 5 m," or "greater than 4 m," or "between 4 m and 5 m" 998 Diffuse; widespread; 3/4's or more: linitis plastia 999 Unknown; size not stated CS Extension (Revised: 12/14/2009) Note 1: INTRALUMINAL or INTRAMURAL extension to esophagus and duodenum is lassified by the depth of greatest invasion in any of these sites, inluding stomah. (For extension to esophagus or duodenum via serosa, see ode 600.) Note 2: If the diagnosis states "linitis plastia" and no other information regarding extension is available, use ode 350. TNM 7 TNM 6 SS77 SS2000 000 In situ; noninvasive; intraepithelial Tis Tis IS IS 050 (Adeno)arinoma in a polyp, noninvasive Tis Tis IS IS 100 Invasive tumor onfined to muosa, NOS (inluding intramuosal, NOS) T1a T1 L L 110 Invades lamina propria T1a T1 L L 120 Invades musularis muosae T1a T1 L L 125 Stated as T1a, NOS T1a T1 L L 130 Confined to head of polyp Extension to stalk T1b T1 L L 140 Confined to stalk of polyp T1b T1 L L 150 Tumor in polyp, NOS T1NOS T1 L L 160 Invades submuosa (superfiial invasion) T1b T1 L L 170 Stated as T1b, NOS T1b T1 L L 200 Invades into but not through musularis propria T2 T2a L L 300 Loalized, NOS Implants inside stomah T1NOS T1 L L 340 Stated as T1, NOS T1NOS T1 L L 29 April 2010 Part II - Upper GI - 59 Version 02.02.00
TNM 7 TNM 6 SS77 SS2000 350 Linitis plastia (see Note 2) and no other information regarding extension is available. T2 T2a RE L 390 Stated as T2, NOS T2 T2NOS L L 400 Invasion through musularis propria or musularis, NOS Extension through wall, NOS Perimusular tissue invaded Subserosal tissue/(sub)serosal fat invaded 450 Extension to adjaent (onnetive) tissue WITHOUT perforation of viseral peritoneum: Gastri artery Ligaments: Gastrooli Gastrohepati Gastrospleni Omentum, NOS Greater Lesser Perigastri fat T3 T2b L L T3 T2b RE RE 480 Stated as T3, NOS T3 T3 RE RE 490 Stated as T4, NOS T4NOS T4 RE RE 500 Invasion of/through serosa (mesothelium) (tunia serosa) (viseral peritoneum), inluding perforation of viseral peritoneum overing the gastri ligaments or the omentum WITHOUT invasion of adjaent strutures Stated as T4a, NOS T4a T3 RE RE 550 (450) + (500) T4a T3 RE RE 600 Diaphragm Duodenum via serosa or NOS Esophagus via serosa Ileum Jejunum Liver Panreas Small intestine, NOS Spleen Transverse olon/mesoolon (inluding flexures) Celiaaxis Aorta T4b T4 RE RE 690 Stated as T4b, NOS T4b T4 RE RE 29 April 2010 Part II - Upper GI - 60 Version 02.02.00
TNM 7 TNM 6 SS77 SS2000 700 Abdominal wall Adrenal gland Kidney Retroperitoneum T4b T4 D D 800 Further ontiguous extension T4b T4 D D 950 No evidene of primary tumor T0 T0 U U 999 Unknown extension Primary tumor annot be assessed TX TX U U CS Tumor Size/Ext Eval (Revised: 08/10/2009) Staging Basis 0 Does not meet riteria for AJCC pathologi staging: No surgial resetion done. Evaluation based on physial examination, imaging examination, or other non-invasive linial evidene. No autopsy evidene used. 1 Does not meet riteria for AJCC pathologi staging: No surgial resetion done. Evaluation based on endosopi examination, diagnosti biopsy, inluding fine needle aspiration biopsy, or other invasive tehniques, inluding surgial observation without biopsy. No autopsy evidene used. 2 Meets riteria for AJCC pathologi staging: p No surgial resetion done, but evidene derived from autopsy (tumor was suspeted or diagnosed prior to autopsy) 3 Either riteria meets AJCC pathologi staging: p Surgial resetion performed WITHOUT pre-surgial systemi treatment or radiation OR surgial resetion performed, unknown if pre-surgial systemi treatment or radiation performed AND Evaluation based on evidene aquired before treatment, supplemented or modified by the additional evidene aquired during and from surgery, partiularly from pathologi examination of the reseted speimen. No surgial resetion done. Evaluation based on positive biopsy of highest T lassifiation. 5 Does not meet riteria for AJCC y-pathologi (yp) staging: Surgial resetion performed AFTER neoadjuvant therapy and tumor size/extension based on linial evidene, unless the pathologi evidene at surgery (AFTER neoadjuvant) is more extensive (see ode 6). 29 April 2010 Part II - Upper GI - 61 Version 02.02.00
Staging Basis 6 Meets riteria for AJCC y-pathologi (yp) staging: yp Surgial resetion performed AFTER neoadjuvant therapy AND tumor size/extension based on pathologi evidene, beause pathologi evidene at surgery is more extensive than linial evidene before treatment. 8 Meets riteria for autopsy (a) staging: a Evidene from autopsy only (tumor was unsuspeted or undiagnosed prior to autopsy) 9 Unknown if surgial resetion done Not assessed; annot be assessed Unknown if assessed CS Lymph Nodes (Revised: 09/15/2009) Note 1: only regional nodes and nodes, NOS, in this field. Distant nodes are oded in the field Mets at DX. Note 2: If information about named regional lymph nodes is available, use odes 100, 400, 420, or 500, rather than odes 600, 650, 700, 710, or 720. TNM 7 TNM 6 SS77 SS2000 000 None; no regional lymph node involvement N0 N0 NONE NONE 29 April 2010 Part II - Upper GI - 62 Version 02.02.00
TNM 7 TNM 6 SS77 SS2000 100 Regional lymph nodes: Left gastri (superior gastri), NOS: Cardial Cardioesophageal Gastri, left Gastropanreati, left Lesser urvature Lesser omental Paraardial Panreatiospleni (panreatiolienal) Panreatoduodenal Perigastri, NOS Peripanreati Right gastri (inferior gastri), NOS: Gastrooli Gastroduodenal Gastroepiploi (gastro-omental), right or NOS Gastrohepati Greater urvature Greater omental Pylori, NOS Infrapylori (subpylori) Suprapylori Spleni (lienal), NOS: Gastroepiploi (gastro-omental), left Spleni hilar Superior mesenteri Nodule(s) in perigastri fat 400 Celia Hepati (exluding gastrohepati, [see ode 100] and hepatoduodenal [see ode 420]) 420 For lesser urvature only: Hepatoduodenal ^ * RN RN ^ * D RN ^ * D D 500 Regional lymph nodes, NOS ^ * RN RN 600 Stated as N1, NOS N1 N1 RN RN 650 Stated as N2, NOS N2 N2 RN RN 700 Stated as N3, NOS N3NOS N3 RN RN 710 Stated as N3a, NOS N3a N3 RN RN 720 Stated as N3b, NOS N3b N3 RN RN 800 Lymph nodes, NOS ^ * RN RN 999 Unknown; not stated Regional lymph node(s) annot be assessed NX NX U U * For odes 100-500 and 800 ONLY: when CS Lymph Nodes Eval is 0, 1, 5, or 9, the N ategory is assigned from the Lymph Nodes Clinial Evaluation Table, using Reg LN Pos and CS Site-Speifi Fator 1; when CS Lymph 29 April 2010 Part II - Upper GI - 63 Version 02.02.00
Nodes Eval is 2, 3, 6, 8, or not oded, the N ategory is determined from the Lymph Nodes Pathologi Evaluation Table Also Used When CS Reg Nodes Eval is Not d using Reg LN Pos. ^ For odes 100-500 and 800 ONLY: when CS Lymph Nodes Eval is 0, 1, 5, or 9, the N ategory is assigned from the Lymph Nodes Clinial Evaluation 7th Table, using Reg LN Pos and CS Site-Speifi Fator 1; when CS Lymph Nodes Eval is 2, 3, 6, 8, or not oded, the N ategory is determined from the Lymph Nodes Pathologi Evaluation 7th Table Also Used When CS Reg Nodes Eval is Not d using Reg LN Pos. CS Lymph Nodes Eval (Revised: 10/26/2009) Note 1: This field is used primarily to derive the staging basis for the N ategory in the TNM system. It reords how the ode for the item "CS Lymph Nodes" was determined based on the diagnosti methods employed and their intent. Note 2: In the 7th edition of the AJCC manual, the linial and pathologi lassifiation rules for the N ategory were hanged to reflet urrent medial pratie. The N is designated as linial or pathologi based on the intent (workup versus treatment) mathing with the assessment of the T lassifiation. When the intent is workup, the staging basis is linial, and when the intent is treatment, the staging basis is pathologi. A. Mirosopi assessment inluding biopsy of regional nodes or sentinel nodes if being performed as part of the workup to hoose the treatment plan, is therefore part of the linial staging. When it is part of the workup, the T ategory is linial, and there has not been a resetion of the primary site adequate for pathologi T lassifiation (whih would be part of the treatment). B. Mirosopi assessment of regional nodes if being performed as part of the treatment is therefore part of the pathologi staging. When it is part of the treatment, the T ategory is pathologi, and there has been a resetion of the primary site adequate for pathologi T lassifiation (all part of the treatment). Note 3: Mirosopi assessment of the highest N ategory is always pathologi (ode 3). Note 4: If lymph node dissetion is not performed after neoadjuvant therapy, use ode 0 or 1. Note 5: Only odes 5 and 6 are used if the node assessment is performed after neoadjuvant therapy. Staging Basis 0 Does not meet riteria for AJCC pathologi staging: No regional lymph nodes removed for examination. Evidene based on physial examination, imaging examination, or other non-invasive linial evidene. No autopsy evidene used. 1 Does not meet riteria for AJCC pathologi staging based on at least one of the following riteria: No regional lymph nodes removed for examination. Evidene based on endosopi examination, or other invasive tehniques inluding surgial observation, without biopsy. No autopsy evidene used. OR Fine needle aspiration, inisional ore needle biopsy, or exisional biopsy of regional lymph nodes or sentinel nodes as part of the diagnosti workup, WITHOUT removal of the primary site adequate for pathologi T lassifiation (treatment). 2 Meets riteria for AJCC pathologi staging: p No regional lymph nodes removed for examination, but evidene derived from autopsy (tumor was suspeted or diagnosed prior to autopsy). 29 April 2010 Part II - Upper GI - 64 Version 02.02.00
Staging Basis 3 Meets riteria for AJCC pathologi staging based on at least one of the following riteria: p Any mirosopi assessment of regional nodes (inluding FNA, inisional ore needle bx, exisional bx, sentinel node bx or node resetion), WITH removal of the primary site adequate for pathologi T lassifiation (treatment) or biopsy assessment of the highest T ategory. OR Any mirosopi assessment of a regional node in the highest N ategory, regardless of the T ategory information. 5 Does not meet riteria for AJCC y-pathologi (yp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on linial evidene, unless the pathologi evidene at surgery (AFTER neoadjuvant) is more extensive (see ode 6). 6 Meets riteria for AJCC y-pathologi (yp) staging: yp Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on pathologi evidene, beause the pathologi evidene at surgery is more extensive than linial evidene before treatment. 8 Meets riteria for AJCC autopsy (a) staging: a Evidene from autopsy; tumor was unsuspeted or undiagnosed prior to autopsy. 9 Unknown if lymph nodes removed for examination Not assessed; annot be assessed Unknown if assessed Reg LN Pos (Revised: 11/18/2009) Note: Reord this field even if there has been preoperative treatment. 00 All nodes examined negative. 01-89 1-89 nodes positive (ode exat number of nodes positive) 90 90 or more nodes positive 95 Positive aspiration or ore biopsy of lymph node(s) 97 Positive nodes - number unspeified 98 No nodes examined 99 Unknown if nodes are positive; not appliable 29 April 2010 Part II - Upper GI - 65 Version 02.02.00
Reg LN Exam (Revised: 03/02/2009) 00 No nodes examined 01-89 1-89 nodes examined (ode exat number of regional lymph nodes examined) 90 90 or more nodes examined 95 No regional nodes removed, but aspiration or ore biopsy of regional nodes performed 96 Regional lymph node removal doumented as sampling and number of nodes unknown/not stated 97 Regional lymph node removal doumented as dissetion and number of nodes unknown/not stated 98 Regional lymph nodes surgially removed but number of lymph nodes unknown/not stated and not doumented as sampling or dissetion; nodes examined, but number unknown 99 Unknown if nodes were examined; not appliable or negative CS Mets at DX (Revised: 06/09/2009) TNM 7 TNM 6 SS77 SS2000 00 No; none M0 M0 NONE NONE 10 Distant lymph node(s): For all subsites: Inferior mesenteri Para-aorti Porta hepatis (portal) (hilar) (in hilus of liver) Retropanreati Retroperitoneal Superior mesenteri or mesenteri, NOS For all subsites EXCEPT lesser urvature Hepatoduodenal Distant lymph nodes, NOS 40 Distant metastases exept distant lymph node(s) (ode 10) Carinomatosis Malignant peritoneal ytology 50 (10) + (40) Distant lymph node(s) plus other distant metastases 60 Distant metastasis, NOS M1, NOS 99 Unknown if distant metastasis Distant metastasis annot be assessed M1 M1 D D M1 M1 D D M1 M1 D D M1 M1 D D M0 MX U U 29 April 2010 Part II - Upper GI - 66 Version 02.02.00
CS Mets Eval (Revised: 08/10/2009) Note: This item reflets the validity of the lassifiation of the item CS Mets at DX only aording to the diagnosti methods employed. Staging Basis 0 Does not meet riteria for AJCC pathologi staging of distant metastasis: Evaluation of distant metastasis based on physial examination, imaging examination, and/or other non-invasive linial evidene. No pathologi examination of metastati tissue performed or pathologi examination was negative. 1 Does not meet riteria for AJCC pathologi staging of distant metastasis: Evaluation of distant metastasis based on endosopi examination or other invasive tehnique, inluding surgial observation without biopsy. No pathologi examination of metastati tissue performed or pathologi examination was negative. 2 Meets riteria for AJCC pathologi staging of distant metastasis: p No pathologi examination of metastati speimen done prior to death, but positive metastati evidene derived from autopsy (tumor was suspeted or diagnosed prior to autopsy). 3 Meets riteria for AJCC pathologi staging of distant metastasis: p Speimen from metastati site mirosopially positive WITHOUT pre-surgial systemi treatment or radiation OR speimen from metastati site mirosopially positive, unknown if pre-surgial systemi treatment or radiation performed OR speimen from metastati site mirosopially positive prior to neoadjuvant treatment. 5 Does not meet riteria for AJCC y-pathologi (yp) staging of distant metastasis: Speimen from metastati site mirosopially positive WITH pre-surgial systemi treatment or radiation, BUT metastasis based on linial evidene. 6 Meets riteria for AJCC y-pathologi (yp) staging of distant metastasis: Speimen from metastati site mirosopially positive WITH pre-surgial systemi treatment or radiation, BUT metastasis based on pathologi evidene. 8 Meets riteria for AJCC autopsy (a) staging of distant metastasis: yp a Evidene from autopsy based on examination of positive metastati tissue AND tumor was unsuspeted or undiagnosed prior to autopsy. 9 Not assessed; annot be assessed Unknown if assessed 29 April 2010 Part II - Upper GI - 67 Version 02.02.00
CS Site-Speifi Fator 1 Clinial Assessment of Regional Lymph Nodes (Revised: 12/31/2009) Note: In the rare instane that the number of linially positive nodes is stated but a linial N ategory is not stated, ode 1-2 nodes as 100 (N1), 3-6 nodes as 200 (N2), 7-15 nodes as 310 (N3a), and 16 or more nodes as 320 (N3b). If the number is only desribed as "more than 7 nodes", ode as 300 (N3, NOS). 000 Nodes not linially evident 100 Clinially N1, NOS 200 Clinially N2, NOS 300 Clinially N3, NOS 310 Clinially N3a 320 Clinially N3b 400 Clinially positive regional nodes, NOS 888 OBSOLETE DATA CONVERTED V0200 See ode 988: Not appliable for this site. 988 Not appliable: Information not olleted for this ase (May inlude ases onverted from ode 888 used in CSv1 for "Not appliable" or when the item was not olleted. If this item is required to derive T, N, M, or any stage, use of ode 988 may result in an error.) 999 Unknown if nodes are linially evident CS Site-Speifi Fator 2 Speifi Loation of Tumor (Revised: 12/31/2009) 010 Fundus - Anterior Wall 020 Fundus - Posterior Wall 030 Fundus, NOS 040 Body - Anterior Wall 050 Body - Posterior Wall 060 Body - Lesser Curvature 070 Body - Greater Curvature 080 Body, NOS 090 Antrum - Anterior Wall 100 Antrum - Posterior Wall 110 Antrum - Lesser Curvature 29 April 2010 Part II - Upper GI - 68 Version 02.02.00
120 Antrum - Greater Curvature 130 Antrum, NOS 150 Overlapping Lesion 888 OBSOLETE DATA CONVERTED V0200 See ode 988: Not appliable for this site 988 Not appliable: Information not olleted for this ase (May inlude ases onverted from ode 888 used in CSv1 for "Not appliable" or when the item was not olleted. If this item is required to derive T, N, M, or any stage, use of ode 988 may result in an error.) 999 Unknown;, NOS CS Site-Speifi Fator 3 (Revised: 06/30/2008) 888 OBSOLETE DATA CONVERTED V0200 See ode 988 Not appliable for this site 988 Not appliable for this shema CS Site-Speifi Fator 4 (Revised: 06/30/2008) 888 OBSOLETE DATA CONVERTED V0200 See ode 988 Not appliable for this site 988 Not appliable for this shema CS Site-Speifi Fator 5 (Revised: 06/30/2008) 888 OBSOLETE DATA CONVERTED V0200 See ode 988 Not appliable for this site 988 Not appliable for this shema 29 April 2010 Part II - Upper GI - 69 Version 02.02.00
CS Site-Speifi Fator 12 (Revised: 06/30/2008) 988 Not appliable for this shema CS Site-Speifi Fator 13 Carinoembryoni Antigen (CEA) (Revised: 11/09/2009) Note: Reord the CEA test results doumented in the medial reord based on information prior to treatment. 000 Test not done 010 Positive/elevated 020 Negative/normal; within normal limits 030 Borderline; undetermined whether positive or negative 988 Not appliable: Information not olleted for this ase 998 Test ordered, results not in hart 999 Unknown or no information CS Site-Speifi Fator 14 Carinoembryoni Antigen (CEA) Lab Value (Revised: 11/09/2009) Note: Reord in nanograms/millileter the highest CEA lab value reorded in the medial reord prior to treatment. Example A pretreatment CEA of 7 nanograms/millileter (ng/ml) would be reorded as 070. 000 0 ng/ml 001 0.1 or less ng/ml 002-979 0.2-97.9 ng/ml 980 98.0 or greater ng/ml 988 Not appliable: Information not olleted for this ase 997 Tests ordered, results not in hart 998 Test not done (test was not ordered and was not performed) 999 Unknown or no information 29 April 2010 Part II - Upper GI - 71 Version 02.02.00
CS Site-Speifi Fator 15 CA 19-9 Lab Value (Revised: 01/27/2010) Note 1: Carbohydrate Antigen 19-9 is a tumor marker that has value in the management of ertain malignanies. Note 2: Reord in Units/milliliter the highest CA 19-9 lab value reorded in the medial reord prior to treatment. Example: A pretreatment CA 19-9 of 60 Units/milliliter (U/ml) would be reorded as 60. 000 0 U/ml 001 0.1 or less U/ml 002-979 0.2-97.9 U/ml 980 98.0 or greater U/ml 988 Not appliable: Information not olleted for this ase 997 Tests ordered, results not in hart 998 Test not done (test was not ordered and was not performed) 999 Unknown or no information CS Site-Speifi Fator 16 (Revised: 02/23/2009) 988 Not appliable for this shema CS Site-Speifi Fator 17 (Revised: 02/23/2009) 988 Not appliable for this shema CS Site-Speifi Fator 18 (Revised: 02/23/2009) 988 Not appliable for this shema CS Site-Speifi Fator 19 (Revised: 02/23/2009) 988 Not appliable for this shema 29 April 2010 Part II - Upper GI - 72 Version 02.02.00
CS Site-Speifi Fator 25 Involvement of Cardia and Distane from Esophagogastri Juntion (EGJ) (Revised: 01/03/2010) Note 1: Sine primary site odes C16.1 (fundus of stomah) and C16.2 (body of stomah) an be assigned to either shema, EsophagusGEJuntion or, this shema disriminator field is needed for the CS Algorithm to determine whih shema to selet only when the site is C16.1 or C16.2. Note 2: In 7th ed., Esophagogastri juntion and the proximal 5 m of the were removed from the shema and added to the Esophagus hapter. Due to differenes in the shemas for Esophagus and, a new shema was reated in CSv2 to aommodate these hanges. In 7th ed., aners whose midpoint is in the lower thorai esophagus, esophagogastri juntion, or within the proximal 5 m of the stomah (ardia) that extend into the esophagogastri juntion or esophagus are stage grouped similar to adenoarinoma of the esophagus. All other aners with a midpoint in the stomah greater than 5 m distal to the esophagogastri juntion, or those within 5 m of the esophagogastri juntion but not extending into the esophagogastri juntion or esophagus, are stage grouped using the gastri aner staging system. Note 3: For ases oded to primary site ode C16.1 or C16.2 and histology: 8000-8152,8154-8231,8243-8245,8247,8248,8250-8934,8940-9136,9141-9582,9700-9701, ode whether or not tumor extends to esophagus (rosses the EGJ) and ode the stated distane of the midpoint of the tumor from the EGJ. This information will be used to determine whether the ase has AJCC TNM and stage group assigned using definitions for esophagus or stomah aners. Note 4: If the primary site ode is stomah and involvement of EGJ and distane from EGJ is unknown but a physiian stages the ase using esophagus definitions, assign to ode 060. Collaborative Stage will use the EsophagusGEJuntion shema to assign TNM and AJCC stage. Shema 000 No involvement of esophagus or EGJ 010 Tumor loated in Cardia or EGJ EsophagusGEJuntion 020 Esophagus or EGJ involved AND distane of tumor midpoint from EGJ 5m or less 030 Esophagus or EGJ involved AND distane of tumor midpoint from EGJ more than 5m 040 Esophagus or EGJ involved AND distane of tumor midpoint from EGJ unknown 050 Esophagus and EGJ not involved but distane of tumor midpoint from EGJ is 5m or less 060 Esophagus involved or esophagus involvement unknown AND distane of tumor midpoint from EGJ more than 5m or unknown AND physiian stages ase using esophagus definitions 100 OBSOLETE DATA RETAINED V0200 C16.1, C16.2 - originally oded in CSv1 999 Involvement of esophagus not stated, unknown or no information, not doumented in patient reord Blank for ases whih are C16.3-C16.9 Blank for Cardia/EGJ ases whih are C16.0 EsophagusGEJuntion EsophagusGEJuntion EsophagusGEJuntion EsophagusGEJuntion 29 April 2010 Part II - Upper GI - 74 Version 02.02.00